| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09.19 | TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years | 616 | Business Wire | 28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib TAGRISSO showed a 52% reduction in risk of central nervous system... ► Artikel lesen | |
| 28.09.19 | LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer | 778 | Business Wire | AstraZeneca and Merck's LYNPARZA added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population
AstraZeneca and Merck Co., Inc., Kenilworth, N.J.,... ► Artikel lesen | |
| 28.09.19 | LYNPARZA (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer | 684 | Business Wire | AstraZeneca and Merck's LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy
AstraZeneca... ► Artikel lesen | |
| 28.09.19 | Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer | 1.572 | Business Wire | Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels Median duration of response for... ► Artikel lesen | |
| 28.09.19 | Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress | 1.087 | Business Wire | Single Agent Activity and Durable Disease Control Across Multiple Tumor Types Data Support the Initiation of a Registration-Enabling Phase 2 Trial Evaluating Single Agent ZW25 in Second-Line... ► Artikel lesen | |
| 28.09.19 | ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor | 537 | Business Wire | AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 3, the main oncogenic TGF-beta isoforms
AVID200 demonstrated peripheral target engagement in a Phase 1 clinical... ► Artikel lesen | |
| 28.09.19 | Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress | 918 | Business Wire | - Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models - Early analysis of data shows stable disease in 54% of evaluable patients at eight... ► Artikel lesen | |
| 28.09.19 | Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer | 1.589 | Business Wire | - Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response - Findings Presented Today at an Oral Session... ► Artikel lesen | |
| 28.09.19 | Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients | 662 | Business Wire | Three-year analysis from Phase 3 CheckMate -238 study represents longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting Bristol-Myers Squibb Company (NYSE: BMY) today announced... ► Artikel lesen | |
| 28.09.19 | Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma | 940 | Business Wire | 52% of patients treated with Opdivo plus Yervoy were alive at five years 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free Results... ► Artikel lesen | |
| 28.09.19 | Upfield lädt eine branchenübergreifende Gruppe von hochgradigen Führungskräften zum Concordia-Jahresgipfel 2019 ein, um politisch für nachhaltige, gesunde, pflanzlich basierte Nahrungsmittelsysteme zu plädieren | 615 | Business Wire | Delegierte der Weltgesundheitsorganisation, der Ernährungs- und Landwirtschaftsorganisation, des World Resources Institute sowie anderer Organisationen kommen zusammen, um eine globale Vision für... ► Artikel lesen | |
| 28.09.19 | Keio Plaza Hotel Tokyo arbeitet mit dem Nationalen Nô-Theater zusammen, um der Welt Japans No-Kultur vorzustellen | 395 | Business Wire | Das Keio Plaza Hotel Tokyo(KPH), eines der prestigeträchtigsten internationalen Hotels Japans in Shinjuku, Tokio, präsentiert vom 27. September bis 27. November 2019 eine Sonderveranstaltung und -ausstellung... ► Artikel lesen | |
| 28.09.19 | Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial | 540 | Business Wire | Growing Body of Evidence Supporting Use of the Tack Endovascular Systemto Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD Intact Vascular, Inc., a developer of medical devices... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 2.372 |
| VARTA | 2.356 |
| RHEINMETALL | 2.240 |
| NEL | 1.990 |
| RENK GROUP | 1.504 |
| NVIDIA | 1.457 |
| DEUTSCHE LUFTHANSA | 1.454 |
| TESLA | 1.427 |
| BAYER | 1.153 |
| AIXTRON SE | 1.112 |
| BYD | 960 |
| SARTORIUS AG VZ | 780 |
| DEUTSCHE BANK | 737 |
| NETFLIX | 707 |
| BASF | 696 |
| EVOTEC | 692 |
| RWE | 657 |
| ALLIANZ | 568 |
| BARRICK GOLD | 561 |
| COMMERZBANK | 554 |
| MERCEDES-BENZ | 554 |
| INFINEON | 551 |
| HENSOLDT | 548 |
| SUPER MICRO COMPUTER | 544 |
| PLUG POWER | 500 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
